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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease in which
pathogenesis and death of motor neurons are triggered by non-cell-autonomous
mechanisms. We showed earlier that exposing primary rat spinal cord cultures to
conditioned media derived from primary mouse astrocyte conditioned media (ACM)
that express human SOD1G93A (ACM-hSOD1G93A) quickly enhances Nav channel-
mediated excitability and calcium influx, generates intracellular reactive oxygen species
(ROS), and leads to death of motoneurons within days. Here we examined the role of
mitochondrial structure and physiology and of the activation of c-Abl, a tyrosine kinase
that induces apoptosis. We show that ACM-hSOD1G93A, but not ACM-hSOD1WT,
increases c-Abl activity in motoneurons, interneurons and glial cells, starting at 60
min; the c-Abl inhibitor STI571 (imatinib) prevents this ACM-hSOD1G93A-mediated
motoneuron death. Interestingly, similar results were obtained with ACM derived from
astrocytes expressing SOD1G86R or TDP43A315T. We further find that co-application
of ACM-SOD1G93A with blockers of Nav channels (spermidine, mexiletine, or riluzole)
or anti-oxidants (Trolox, esculetin, or tiron) effectively prevent c-Abl activation and
motoneuron death. In addition, ACM-SOD1G93A induces alterations in the morphology
of neuronal mitochondria that are related with their membrane depolarization. Finally,
we find that blocking the opening of the mitochondrial permeability transition pore with
cyclosporine A, or inhibiting mitochondrial calcium uptake with Ru360, reduces ROS
production and c-Abl activation. Together, our data point to a sequence of events in
which a toxic factor(s) released by ALS-expressing astrocytes rapidly induces hyper-
excitability, which in turn increases calcium influx and affects mitochondrial structure and
physiology. ROS production, mediated at least in part through mitochondrial alterations,
trigger c-Abl signaling and lead to motoneuron death.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal paralytic disorder
caused by the progressive degeneration of upper and lower
motoneurons during adulthood, and results in death by
respiratory failure, usually within 3–5 years of diagnosis. The
majority of ALS cases are sporadic (sALS), but ∼10% are
familial (fALS) and are generated by mutations in at least
24 identiﬁed ALS-associated gene loci, including those for
superoxide dismutase (SOD1) and transactive response DNA-
binding protein 43 (TDP-43), as well as by hexanucleotide
expansion in C9orf72 (Bento-Abreu et al., 2010; DeJesus-
Hernandez et al., 2011; Ferraiuolo et al., 2011; Renton et al.,
2011, 2014; Wegorzewska and Baloh, 2011; Sreedharan and
Brown, 2013). Much of our understanding of ALS, however,
is based on a subgroup of fALS patients who carry mutations
in the gene that encodes SOD1; the exact mechanisms how
SOD1 becomes toxic have not been elucidated (Cleveland
and Rothstein, 2001; Pasinelli and Brown, 2006). In vivo
and in vitro studies with transgenic ALS animal models
(especially with the SOD1G93A mice) yielded the identiﬁcation
of pathogenic changes in aﬀected motoneurons: these alterations
include mitochondrial dysfunction, hyper-excitability, glutamate
excitotoxicity, nitroxidative stress from reactive oxygen species
(ROS) or reactive nitrogen species (RNS; collectively leading
to nitroxidative stress), protein aggregation and misfolding,
proteasome impairment, cytoskeletal disruption, activation of
cell death signals, and dysregulation of transcription and RNA
processing (Cleveland and Rothstein, 2001; Bruijn et al., 2004;
Pasinelli and Brown, 2006; Ferraiuolo et al., 2011; Cozzolino et al.,
2012; van Zundert et al., 2012).
An increasing number of in vitro studies report that
astrocytes that express mutant SOD1 selectively kill motoneurons
through non-cell-autonomous toxicity (Vargas et al., 2006;
Di Giorgio et al., 2007; Nagai et al., 2007; Cassina et al., 2008;
Marchetto et al., 2008; Haidet-Phillips et al., 2011; Castillo et al.,
2013; Fritz et al., 2013; Meyer et al., 2014; Re et al., 2014;
Rojas et al., 2014). Studies of interactions between neurons
and astrocytes suggest that similar pathogenic changes occur in
human ALS patients and in transgenic ALS models, including
those that are based on mitochondrial dysfunction, hyper-
excitability, and nitroxidative stress, underscoring the value of
these model systems (Cassina et al., 2008; Marchetto et al.,
2008; Fritz et al., 2013; Rojas et al., 2014). Despite substantial
progress in the identiﬁcation of pathogenic changes, as well as
of the cell types that contribute to them, no cure exists for
this profoundly debilitating disease, and the mechanisms that
underlie motoneurons death in ALS remain largely unknown; in
fact, we do not know even whether the neuronal abnormalities
are a primary or secondary event, or whether they result from
a compensatory mechanism (van Zundert et al., 2012). In part
this is because classical approaches for studying neuron-glial
interactions use a co-culture system wherein neurons are grown
on a feeder layer of astrocytes, thus masking the temporal
interplay between original and secondary pathogenic events.
To circumvent this, we use astrocyte conditioned media
(ACM), secreted by primary astrocytes derived from transgenic
ALS mouse models (including ACM-SOD1G93A), and expose
primary wild-type (WT) rat spinal cord cultures (4 DIV) to
this ACM for varying times (mins, hours, days). Use of this in
vitro system, along with electrophysiological recordings, calcium
imaging, immunostaining and pharmacology, led us to determine
that applying ACM-hSOD1G93A, but not ACM-hSOD1WT, to
primary WT spinal cord cultures rapidly increases the neurons’
evoked action potentials (eAPs; starting at 15–20 min after ACM
exposure); this is followed by calcium inﬂux and the generation of
intracellular nitroxidative stress (ROS/RNS; starting at 30 min),
thereby leading to speciﬁc and robust motoneuron death within
days (Fritz et al., 2013; Rojas et al., 2014).
Here we wanted to establish the mechanisms whereby
ROS/RNS mediates pathogenesis and death of motoneurons, and
focused on the interplay between oxidative stress, mitochondrial
structure and physiology, and c-Abl activation; these processes
are linked to ALS pathology and inﬂuenced by ROS. Although
the link between oxidative stress and impaired mitochondrial
function has been established in diverse ALS model systems
(von Lewinski and Keller, 2005; Grosskreutz et al., 2010; Carrì
and Cozzolino, 2011; Drechsel et al., 2012; Tan et al., 2014),
use of conventional co-culture systems has yielded little about
the causal relationship between the stress and the dysfunction.
Previous studies also have implicated active c-Abl in a variety of
neurodegenerative diseases, including in ALS (Katsumata et al.,
2012), Alzheimer’s disease (Alvarez et al., 2004; Cancino et al.,
2008; Estrada et al., 2011; Gonzalez-Zuñiga et al., 2014), and
Parkinson’s disease (Ko et al., 2010; Imam et al., 2011, 2013).
In addition to its classic function in leukemia pathogenesis,
the c-Abl no-receptor tyrosine kinase plays a role in neuronal
development and is required for the proper functioning of
diﬀerentiated neurons (Moresco and Koleske, 2003; Hernández
et al., 2004; Bradley and Koleske, 2009). Activated c-Abl has
important roles in neuronal cytoskeleton remodeling, promotes
dendritogenesis, and regulates adhesion, migration and growth
cone path-ﬁnding (Koleske et al., 1998; Lu et al., 2002; Rhee
et al., 2002; Woodring et al., 2002; Moresco et al., 2003); these
processes, as well as cell death, are dependent on the activation
c-Abl by of phosphorylation of its tyrosine 245 (Tyr245) and
tyrosine 412 (Tyr412; Zhu and Wang, 2004; Gonﬂoni et al.,
2012). In the hippocampus, c-Abl is localized in both the pre-
and postsynaptic regions and regulates synaptic structure and
function (Moresco et al., 2003; Perez de Arce et al., 2010; Vargas
et al., 2014). The contribution of c-Abl signaling activation to
neuronal apoptosis has also been reported. For example, it has
been shown that c-Abl regulates the choice between cell survival
in an arrested state and apoptosis (Wang, 2005), controlling the
function and stabilization of p73 in response to genotoxic stress
(Tsai and Yuan, 2003). In addition, c-Abl and Cdk5 cooperatively
regulate the maximal activation of p53, which results in neuronal
apoptosis in response to oxidative stress by hydrogen peroxide
(Levav-Cohen et al., 2005; Lee et al., 2008). c-Abl is activated by
a wide range of stimuli, including inﬂammation, DNA damage,
amyloid beta, and oxidative stress (van Etten, 1999; Klein et al.,
2011; Schlatterer et al., 2011b).
In the present study, we used the ACM-SOD1G93A in
vitro model system, together with immunostaining, real-time
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imaging with ﬂuorescent markers for nitroxidative stress and
mitochondrial membrane depolarization, electron microscopy,
as well as pharmacological treatments, to demonstrate that
c-Abl activation and mitochondrial swelling and membrane
depolarization play key roles in the pathogenesis and death
of motoneurons induced by toxic factor(s) released from
SOD1G93A-expressing astrocytes. Our ﬁndings suggest that
mitochondria are an important, but not an exclusive, source
of ROS/RNS production which activates the c-Abl signaling
pathway. And ﬁnally, we use diverse compounds that reduce
Nav channel activity and extracellular calcium levels, to unveil
that hyper-excitability and calcium inﬂux into the cytoplasm
occur upstream of ROS/RNS production, alterations on the
mitochondrial structure and membrane potentiation, and c-Abl
activation.
Materials and Methods
Animals
Care and use of rodents was in accordance with the US
National Institute of Health guidelines, and was approved
by the Institutional Animal Care and Use Committee of
Andres Bello University. Hemizygous transgenic mice carrying
mutant human SOD1G93A (high copy number; B6SJL; Cat.
No. 002726) and WT human SOD1WT (B6SJL; Cat. No.
002297) were originally obtained from Jackson Laboratories (Bar
Harbor, ME, USA). Non-transgenic littermates and transgenic
mice over-expressing the gene for human SOD1WT were
used as controls. Transgenes were identiﬁed by polymerase
chain reaction (Wegorzewska et al., 2009; Castillo et al.,
2013; Fritz et al., 2013). The SOD1G93A mice, but not
the hSOD1WT mice, develop signs of neuromuscular deﬁcits
(tremor of the legs and loss of extension reﬂex of the
hind paws) starting at 3 months of age and have an
average lifespan of 19–21 weeks (Gurney et al., 1994).
Mice carrying SOD1G86R (Ripps et al., 1995) or TDP43A315T
(Wegorzewska et al., 2009) develop similar loss of motor function
between 3 and 4 months and do not survive to the age of
4 months.
Conditioned Media Preparation
Astrocyte-onditioned media was prepared as described (Nagai
et al., 2007; Castillo et al., 2013; Fritz et al., 2013; Rojas et al.,
2014). Brieﬂy, cultures of astrocytes were prepared from P1-2WT
mice and from ALS transgenic mice. Cultures were maintained
in DMEM (Hyclone, Cat. No. SH30081.02) containing 10%
FBS (Hyclone, Cat. No. SH30071.03; lot ATC31648) and 1%
penicillin–streptomycin (Gibco, Cat. No. 15070-063) at 37◦C 5%
CO2. Cultures reached conﬂuence after 2–3 weeks and contained
>95% GFAP+ astrocytes. Residual microglia were removed by
shaking cultures in an orbital shaker (200 r.p.m. in the incubator)
overnight (7 h), at which point media was replaced by spinal
culture media (see below). After 7 days, ACM was collected,
centrifuged (500 g for 10 min) and stored at −80◦C; before
use, it was supplemented with 4.5 mg ml−1 D-glucose (ﬁnal
concentration) and penicillin/streptomycin, and ﬁltered. A chick
hindlimb muscle extract was also added to the ACM before use
(Sepulveda et al., 2010).
While in Nagai et al. (2007) the ACM-hSOD1G93A is added to
the cultures undiluted, for all our experiments presented here and
previously the ACM-hSOD1G93A as well as the ACM-hSOD1WT
was diluted 8–10 fold. The exact dilution was determined
for each new batch of ACM by comparing the motoneuron
toxicity of the ACM from transgenic animals carrying the ALS-
causing mutants (ACM-hSOD1G93A, ACM-SOD1G86R or ACM-
TDP43A315T) to that of ACM generated from mice carrying
the WT human SOD1 gene (ACM-hSOD1WT) or from non-
transgenic littermates; at the selected dilutions the conditioned
media derived from the astrocytes expressing the ALS-causing
genes robustly killed motoneurons, whereas the control media
did not aﬀect motoneuron survival. The ACM was applied to
ventral spinal cord cultures derived from rats because better
quality motoneurons are obtained from rats than from mice;
a number of studies have shown that such mixed species co-
cultures (from rat, mice, human) do not appear to induce any
side eﬀects (e.g., Pehar et al., 2004; Di Giorgio et al., 2007; Nagai
et al., 2007; Castillo et al., 2013; Fritz et al., 2013; Re et al., 2014;
Rojas et al., 2014).
Primary Spinal Cord Neuronal Cultures
Pregnant Sprague-Dawley rats were deeply anesthetized with
CO2, and primary spinal cultures were prepared from E14
pups (Sepulveda et al., 2010; Fritz et al., 2013; Rojas et al.,
2014). Brieﬂy, whole spinal cords were excised and placed
into ice-cold HBSS (Gibco, Cat. No. 14185-052) containing
50 μg/ml penicillin/streptomycin (Gibco, Cat. No. 15070-063).
The dorsal part of the spinal cord was removed using a small
razor blade, and the ventral cord was minced and enzymatically
treated by incubating in pre-warmed PBS 1x containing 0.25%
trypsin (Gibco, Cat. No. 15090-046) for 20 min at 37◦C.
Cells were transferred to a 15 ml tube containing neuronal
growth media containing 70% MEM (Gibco, Cat. No. 11090-
073), 25% Neurobasal media (Gibco, Cat. No. 21103-049), 1%
N2 supplement (Gibco, Cat. No. 17502-048), 1% L-glutamine
(Gibco, Cat. No. 25030-081), 1% penicillin–streptomycin (Gibco,
Cat. No. 15070-063), 2% horse serum (Hyclone, Cat. No.
SH30074.03; lot AQH24495) and 100 mM sodium pyruvate
(Gibco, Cat. No. 11360-070); they were precipitated, transferred
to a new 15-ml-tube containing 2 ml of growth media, re-
suspended by mechanical agitation through ﬁre-polished glass
Pasteur pipettes of diﬀerent tip diameters, and counted; 4,8× 106
cells were plated on freshly prepared poly-L-lysine-coated 24-well
plates (1 mg/ml; 30.000–70.000 MW; Sigma, Cat. No. P2636).
Cells were cultured for 7 days at 37◦C under 5% CO2, and
supplemented with 45 μg/ml chick leg extract (Sepulveda et al.,
2010); the media was refreshed every 3 days.
Cell Survival Analysis
To measure survival of motoneurons and interneurons, cultures
were immunolabeled and counted as previously described
(Sepulveda et al., 2010; Castillo et al., 2013; Fritz et al., 2013; Rojas
et al., 2014). Brieﬂy, primary spinal cultures were ﬁxed at 7 DIV
with 4% paraformaldehyde, and immunostained with a rabbit
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polyclonal antibody against MAP2 (1:400; Cat. No. sc-20172;
Santa Cruz Biotechnology) to label all neurons (interneurons
plus motoneurons) and with a mouse monoclonal SMI-32
antibody (1:600, Cat. No. SMI-32R; Sternberger Monoclonals)
to reveal the presence of unphosphorylated neuroﬁlament-
H, which is expressed speciﬁcally in motoneurons in spinal
cord cultures (Urushitani et al., 2006; Nagai et al., 2007);
previously we found that our WT primary spinal cultures
typically contain at least 8–10% motoneurons until 12 DIV
(Sepulveda et al., 2010). Fluorescent neurons were visualized with
epiﬂuorescent illumination on an Olympus IX81 microscope
or on a Nikon C1 confocal microscope on which stacks of
0.50-μm optical sections were acquired through entire neurons.
Labeling patterns were documented with a 20x objective and
a Q-Imaging Micropublisher 3.3 Real-Time Viewing camera;
MAP2- and SMI-32-positive neurons were counted oﬀ-line
within 20 randomly chosen ﬁelds, and the percentage of SMI-32-
positive motoneurons within the total number of MAP2-positive
cells was calculated. Each condition was replicated in at least three
independent cultures and in duplicate.
Pharmacological Treatments in Culture
Mexiletine (Tocris, Cat. No. 2596) was dissolved in water to
100 mM and used at ﬁnal concentration of 25 nM. Riluzole
(Sigma, Cat. No. R116) was dissolved in distilled water (plus
10% Tween20) at 100 μM, and added to cultures to ﬁnal
concentration of 100 nM. Spermidine (Sigma, Cat. No. S2626)
was dissolved in water at 100 mg/ml and added to cultures to a
ﬁnal concentration of 10 μM. Trolox (Sigma, Cat. No. 238813)
was dissolved in distilled water at 100 mM and added to cultures
to ﬁnal concentration of 1 μM. Esculetin (Sigma, Cat. No. 17795)
was dissolved in dimethyl sulfoxide (DMSO), and added to
cultures to ﬁnal concentration 25 μM. Tiron (Sigma, Cat. No.
D7389) was dissolved in distilled water at 100 mM and added
to cultures to ﬁnal concentration of 25 μM. Ru360 (Calbiochem
Cat. No 557440) was dissolved in water at 0.5 mg/mL and added
to cultures to ﬁnal concentration 5 μM. Cyclosporin A (CsA),
(Sigma Cat. No. 30024) was dissolved in DMSO at 50 mM, and
added to cultures to ﬁnal concentration 10 μM. EGTA (Sigma
Cat. No. E3839) was dissolved at 100 mM in NaOH 1M, and
added to cultures to a ﬁnal concentration of 200 μM. All stock
solutions were stored at −20◦C.
c-ABL Immunofluorescence Labeling
For identiﬁcation c-Abl phosphorylation in speciﬁc cell
types, primary spinal cultures were ﬁxed at 7 DIV with 4%
paraformaldehyde, and immunostained with a rabbit polyclonal
antibody against MAP2 and SMI-32 antibody, as indicated above
in the section “cell survival analysis.” A mouse monoclonal
antibody anti-glial ﬁbrillary acidic protein (GFAP; 1:600, Sigma,
Cat. No. G393) was also used. For detecting active c-Abl, a mouse
monoclonal antibody recognizing phosphorylated Tyr-412
(1:1000 for slices; 1:600 for cultures in vitro; 1:2000 for western
blot; Sigma; Cat. No. C5240) was used. For immunostainings in
tissue, hSOD1G93A (>P120) and hSOD1G86R (P95) transgenic
mice were sacriﬁced, perfused with 4% PFA and sectioned in
crytostat obtaining 40 μm slices. All antibody bindings were
visualized with the appropriate Alexa ﬂuorescent secondary
antibodies (1:500; Life Technologies). Our WT primary spinal
cord cultures typically contain at least 6–10% motoneurons
until 12 DIV (Sepulveda et al., 2010). Immunolabeled neurons
were documented on an upright Olympus Fluoview 1000
confocal microscope (60x oil objective) or a Nikon Eclipse Ti-U
microscope equipped with a SPOT PursuitTM USB Camera
CCD (14-bit), Epi-ﬂ Illuminator, mercury lamp and Sutter
Smart-Shutter with a lambda SC controller. For quantiﬁcation of
cell number, cultures were photographed using a 20x objective;
MAP2- and SMI-32-positive neurons were counted oﬄine
within 20 randomly chosen ﬁelds, and the percentage of SMI-32-
positive motoneurons within the total number of MAP2-positive
cells was calculated. Each condition was replicated in at least
three independent cultures, and in duplicate. For phospho-
c-Abl quantiﬁcation in cultures, ﬂuorescence intensity was
quantiﬁed using ImageJ software (NIH, Bethesda, MD, USA).
Brieﬂy, cell body was marked manually to set a region of
interest. The mean ﬂuorescence was quantiﬁed for each cell
and the background was subtracted choosing a region without
cells. The ﬂuorescence corresponding to control cells were
normalized at 1.
Mitochondrial Membrane Potential
Measurements with TMRM
Changes in mitochondrial membrane potential (mt) were
determined with the potentiometric dye tetramethyl rhodamine
methyl ester, TMRM (Molecular Probes, Cat. No. T-668). At
4 DIV primary ventral spinal cord cultures were washed twice
with Hanks solution (Invitrogen, Cat. No. 4025134), loaded in
an incubator for 30 min at 37◦C, 5% CO2 and in the dark
with 50 nM of the TMRM dye diluted in Hanks solution.
Immediately after, the ﬂuorescent signal was acquired at two
time points: before (time 0 min) and 30 min following ACM-
hSOD1G93A addition. The excitation and emission wavelengths
of TMRM ﬂuorescent dye are 550 and 575 nm, respectively. The
pictures were taken using Olympus IX81 (Olympus) microscope
equipped with a digital camera Orca-R2 (Hamatsu) at the 100X
magniﬁcation. Scale bar 20 μm. At least three independent ﬁelds
were acquired for each condition and at least 10 cells were
used for quantiﬁcation of the ﬂuorescence signal. Cells were
marked by drawing a region of interest around the cell body,
and mean ﬂuorescence intensity was calculated for each cell after
subtraction of the background signal using the image analysis
module in ImageJ software.
Nitroxidative Stress Measurements with
CM-H2DCF-DA
The intracellular levels of ROS/RNS were measured with CM-
H2DCFDA (Invitrogen, Cat. No. C6827) as previously described
(Rojas et al., 2014). H2DCF-DA is not a speciﬁc probe for a
speciﬁc oxidant and has been used to monitor certain ROS/RNS
(see Discussion). The CM-H2DCF-DA stock solution (1 mM)
was prepared in DMSO and was diluted in the culture medium
to a ﬁnal concentration of 1 μM just before addition to the cells.
After application of the diverse ACMs to the spinal cord cultures
for diﬀerent time (minutes-hours-days), cells were washed
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(PBS 1x) to remove the ACMs and exposed to CM-H2DCF-
DA for 30 min at 37◦C in dark, to label both motoneurons
and interneurons. To facilitate the CM-H2DCF-DA membrane
penetration, 0.004% Pluronic acid F-127 (Invitrogen, Cat. No.
P-3000MP) was added to the culture medium to facilitate dye
entry, eliminate possible hydrolysis of dyes by external esterases
and maintain better cell integrity (Appaix et al., 2012). After the
incubation time, the CM-H2DCF-DA-cointaing culture medium
was removed and cultures were washed twice with PBS 1X and
suspended in culture medium (500 μl ﬁnal volume). Next, cells
were immediately imaged using an upright Nikon Eclipse Ti-
U microscope equipped with a SPOT PursuitTM USB Camera
CCD (14-bit), Epi-ﬂ Illuminator, mercury lamp and Sutter Smart-
Shutter with a lambda SC controller. Cells were photographed
using a 20x objective. As CM-H2DCF-DA is a non-ﬂuorescent
dye it passively diﬀuses into cells and is hydrolyzed intracellularly
to the DCFH carboxylate anion that is trapped inside; oxidation
of DCFH results in the formation of the ﬂuorescent product
DCF, with excitation and emission wavelengths λex/λem = 492–
495/517–527 nm. The exposure time was kept below 4 s in
order to avoid photo-oxidation of the ROS/RNS sensitive dye
and for all given treatments ﬁelds were exposed for exactly
the same amount of time. At least three independent ﬁelds
were acquired for each condition and at least 10 cells per ﬁeld
were used for quantiﬁcation of the ﬂuorescence signal. Cells
were masked by drawing a region of interest around the cell
body, and mean ﬂuorescence intensity was calculated for each
cell after subtraction of the background signal using the image
analysis module in ImageJ software. All cells, independent of
ttheir relative intensity unit (RIU), were included in the analysis.
Cultures were also incubated with H2O2 (200 μM for 20 min) to
serve as a positive control.
Electron Microscopy
For electron microscopy analysis, ventral spinal cord cultures
were processed as previously described (Villegas et al., 2014).
Brieﬂy, cells were ﬁxed at 4◦C o.n. with ultrastructure solution
(2.5% glutaraldehide; 0.1 M picric acid; 0.05 M cacodylate buﬀer;
pH 7.4). Cultures were wash in the same buﬀer, immersed in
1% OsO4 for 1 h followed by a 2 h in block incubation with
2% uranyl acetate. Cultures were then dehydrated using a graded
series of ethanol, propylene oxide and inﬁltrated with Epon (Ted
Pella Inc.). Ultrathin sections were contrasted with 1% uranyl
acetate and lead citrate. Grids were observed with a Philips Tecnai
12 electron microscope operated at 80 kV. Negative ﬁlms were
developed and scanned.
Western Blot
The spinal cord and brain from post-symptomatic hSOD1G93A
and control WT mice were lysed in RIPA buﬀer (50 mM Tris-
HCL pH 7,4; 1% NP-40; 0,5% Na-deoxycholate, 0,1% SDS,
150 mM NaCl and 2 mM EDTA) with protease inhibitor
cocktail (Roche, Complete min tables Cat. No. 11836153001)
and phosphatase inhibitors [10 mM sodium orthovanadate and
50 mM sodium ﬂuoride (New England Biolabs, Ipswich, MA,
USA)]. Protein concentrations were determined using micro
BCA Protein Assay Kit (Thermo Scientiﬁc, Rockford, IL, USA).
Protein samples (30 μg per lane loaded) were separated by
10% SDS-polyacrilamide gel electrophoresis (PAGE) and then
transferred to a nitrocellulose membrane (Thermo Scientiﬁc,
Rockford, IL, USA). Primary antibodies were used at following
dilutions: unphosphorylated anti-c-Abl, 1:1000 (Santa Cruz, USA
Cat. No. sc-56887); anti-n-cadherin 1:1000 (Santa Cruz, USA,
Cat. No. sc-271386). For detecting active c-Abl, rabbit polyclonal
antibody recognizing phosphorylated Tyr-412 (1:2000; Sigma;
Cat No C5240) were used. Secondary antibodies were used at
1:2000 and detection was performed using ECLWestern Blotting
Substrate (Thermo Scientiﬁc, Rockford, IL, USA). Anti-phospho-
c-Abl was diluted in 5% fat-free milk in TBS plus 0.5% Tween-20
(Winkler, Chile), otherwise 5% fat-free milk in PBS plus 0.5%
Tween-20 was used.
Data Analysis
ANOVA, followed by post hoc Tukey tests, was used to detect
signiﬁcant changes. Student’s t-tests were used to compare the
response of two cell populations to individual treatments. Unless
otherwise stated, error bars represent the mean± SEM; ∗p≤ 0.05,
∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001 vs. control; #p < 0.05, ##p < 0.01,
###p < 0.001 compared to ACMs.
Results
ACM-hSOD1G93A Rapidly Increases
Phosphorylation of c-Abl in Motoneurons,
Interneurons and Astrocytes
We ﬁrst examined whether c-Abl is phosphorylated in the central
nervous system of symptomatic mice that express hSOD1G93A.
Immunostaining assays as well as western blots of whole lysate
extracts from the spinal cord and brain were used to determine
the expression of native c-Abl proteins and of c-Abl that is
phosphorylated on tyrosine 412 (Tyr412; a site that enhances
c-Abl catalytic activity; Hantschel and Superti-Furga, 2004). In
agreement with a previous study (Katsumata et al., 2012), we
found a robust increase in the phosphorylation of c-Abl in
the brain and spinal cord of symptomatic hSOD1G93A mice
(P120), compared to non-transgenic littermates; however, unlike
this earlier study, our samples did not show an increase in
the levels of expression of native c-Abl (Supplementary Figure
S1). Interestingly, we also found similar increases in c-Abl
phosphorylation levels in the spinal cord and motor cortex of
symptomatic SOD1G86R mice (P95; Supplementary Figure S2).
To investigate whether soluble toxic factor(s) released by
astrocytes that carry the hSOD1G93A mutation can trigger the
activation of c-Abl, we exposed 4 DIV ventral spinal cord cultures
to ACM-hSOD1G93A, ﬁxed the cells at diﬀerent post treatment
times (0–120 min), and immunostained with an antibody against
phosphorylated c-Abl (Tyr412; Figure 1A). To assess which
cell type in our model system displays phosphorylated c-Abl,
we used an antibody against microtubule-associated protein 2
(MAP2; recognizing interneurons and motoneurons), the SMI-
32 antibody (recognizing motoneurons in ventral spinal cord
cultures), and an antibody against the glial ﬁbrillary acidic protein
(GFAP; expressed in astrocytes). Analysis of the immunostaining
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FIGURE 1 | Continued
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FIGURE 1 | Continued
Exposure of primary spinal cord cultures to ACM-SOD1G93A induces increases in c-Abl phosphorylation. (A) Flow diagram of experiment. Primary
wild-type (WT) rat spinal cord cultures (4 DIV) were exposed to ACM derived from transgenic mice overexpressing SOD1G93A (ACM-SOD1G93A) for 0–120 min. Next
cultures were washed, fixed and immunostained with an antibody recognizing phosphorylated c-Abl (Tyr-412) and cell markers to define cell type. (B) Spinal cord
cultures untreated (0 min; upper images) or treated with ACM-SOD1G93A for 90 min (lower images) were triple-labeled with anti-microtubule-associated protein 2
(MAP2) antibody (white) to visualize neurons (arrow show interneuron that is MAP2+/SMI32− ), with the SMI-32 antibody (red) to identify motoneurons (arrowhead),
and with the phospho-c-Abl antibody (green) to show active c-Abl. Cultures were also stained with DAPI to visualize their nucleus. Inset shows selected motoneuron
in the merge. Scale bar, 25 μm. (C) Spinal cord cultures untreated (0 min; upper images) or treated for 90 min with ACM-SOD1G93A (lower images) were
triple-labeled with anti-MAP2 antibody (white) to visualize neurons (arrows), with the GFAP antibody (red) to identify astrocytes (arrowhead), and with the
phospho-c-Abl antibody (green) to show active c-Abl. Inset shows selected astrocyte in the merge. Scale bar, 25 μm. (D) Graphs showing the c-Abl-P fluorescent
intensity (relative intensity unity; RIU) at 0, 30, 60, 90, and 120 min after application of ACM-SOD1G93A (red line): immunestaining was used to identify c-Abl-P within
a particular cell type, including in motoneurons (D1; MAP2+/SMI32+ ), interneurons (D2; MAP2+/SMI32− ), and glial cells (D3; MAP2−/GFAP+ ). Results obtained
ACM-SOD1WT are also included (gray lines). In all experiment, H2O2 (200 μM for 20 min) served as positive control. Note that c-Abl-P fluorescence peaked in all
three cell types after 90 min of incubation with ACM-SOD1G93A. (E) Graphs showing the percentage of motoneurons (E1), interneurons (E2), and glial cells (E3)
positive for c-Abl-P after 90 min (at peak) of exposure to ACM-SOD1G93A. Values represent mean ± SEM from at least three independent experiments performed in
duplicate, analyzed by ANOVA (D) or t-test (E). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. control.
revealed that in ventral spinal cord cultures at 4 DIV, ∼4%
of the cells are motoneurons (MAP2+/SMI32+/GFAP−), ∼37%
are interneurons (MAP2+/SMI32−/GFAP−), and ∼59% are
astrocytes (MAP2+/SMI32−/GFAP−; data not shown). Using
this staining strategy to identify cell types, we show that acute
application of ACM-hSOD1G93A to 4 DIV spinal cord cultures
induces a robust phosphorylation of c-Abl in motoneurons
(arrowheads and inset in Figure 1B) and interneurons (arrows
in Figure 1B) and astrocytes (arrowheads and insets in
Figure 1C). Quantiﬁcation of ﬂuorescence shows that intensity
speaks for all three cell types at 90 min of ACM-hSOD1G93A
exposure (red lines in graphs Figures 1D1−3). Strong c-Abl
phosphorylation was also produced in spinal cord cultures by
short-term application of H2O2 (200 μM for 20 min; green
squares in Figures 1D1−3). Additional analysis of the number
of cells that were immunopositive for phosphorylated c-Abl
revealed that following 90 min of exposure to ACM-hSOD1G93A
all motoneurons (100%; Figure 1E1), plus the vast majority
of interneurons (>80%; Figure 1E2) and astrocytes (>90%;
Figure 1E3) expressed the activated form of c-Abl. Analysis of the
subcellular distribution of phosphorylated c-Abl further revealed
that ACM-hSOD1G93A leads to a homogenous distribution of this
activated tyrosine kinase in all three cell types (Figures 1C–E1;
insets). Of note is that increases in activated c-Abl also occurs in
the cell’s nucleus where it can perform its pro-apoptotic function
and repress neuronal genes expression (Zhu and Wang, 2004;
Yoshida, 2008; Gonzalez-Zuñiga et al., 2014). Interestingly, we
also detected similar increases in c-Abl phosphorylation levels
in motoneurons that were subjected to ACM derived from
astrocytes expressing SOD1G86R or TDP43A315T (Supplementary
Figure S3). In contrast, control ACM obtained from astrocytes
that are harvested from transgenic mice carrying the non-
pathological WT human SOD1 gene (ACM-hSOD1WT) did not
induce c-Abl phosphorylation in any of the three cell types
(Figures 1D1−3; gray lines).
Treatment of Cultures with c-Abl Inhibitor
STI571 Prevents Motoneuron Cell Death
Induced by ACM-hSOD1G93A
To determine whether the increased phosphorylation of c-Abl
induced by ACM-hSOD1G93A contributes to motoneuron
death, 4 DIV spinal cord cultures were co-incubated with
ACM-hSOD1G93A plus the c-Abl kinase inhibitor STI571,
and motoneuron survival (MAP2+/SMI32+) was assessed at
7 DIV (Figure 2A). We ﬁrst used immunostaining (as in
Figure 1) to assess the eﬀectiveness of STI571 in preventing
c-Abl phosphorylation in the three spinal cord cell types.
STI571, also called imatinib, when applied at micromolar
levels to primary neuronal cultures eﬀectively inhibits the
phosphorylation of c-Abl following various stimuli, including
oxidative stress (Alvarez et al., 2004, 2008; Cancino et al.,
2011; Klein et al., 2011). We found that 4 DIV cultures
treated for 90 min with both ACM-hSOD1G93A and 2 μM
STI571 displayed a signiﬁcant reduction in the intensity of
immunoreactivity for phosphorylated c-Abl (Figures 2B1−3)
and in the percentage of cells that were positively stained
(Supplementary Figures S4B1−3); these changes were observed
for motoneurons (Figure 2B1), interneurons (Figure 2B2), and
astrocytes (Figure 2B3). Following chronic treatment of the
cultures with ACM-hSOD1G93A plus STI571, and analyzed 3 days
later (at 7 DIV), we found that the reduction in intensity
(Figures 2C1−3) and in the percentage of cells positive for
phosphorylated c-Abl (Supplementary Figures S4C1−3) was
maintained in all three cell types. Importantly, application of
STI571 was able to prevent motoneuron cell death induced
by SOD1G93A (Figure 2D). Similarly, STI571 prevented also
motoneuron cell death induced by SOD1G86R or TDP43A315T
(Supplementary Figures S3C–E). These results document that
activation of c-Abl in two completely unrelated ALS models
leads to the death of motoneurons. In contrast to the ACMs
obtained from ALS astrocytes, chronic application of STI571
with control ACM-hSOD1WT did not alter c-Abl intensity in
motoneurons (Figure 2C4) or number of surviving motoneurons
(Figure 2E). Collectively, these results indicate that the favorable
eﬀects of STI571 are not a result of a non-speciﬁc beneﬁcial
inﬂuence of this compound, but rather that the inhibitor drug
counterbalances the toxic eﬀects of ACM-hSOD1G93A. Because
ACM-hSOD1WT did not induce a signiﬁcant change in the
phosphorylation of c-Abl, in motoneuron cell survival, or in
ROS/RNS production (as also shown previously; Fritz et al., 2013;
Rojas et al., 2014), results from use of the control ACM are
omitted from most ﬁgures.
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FIGURE 2 | c-Abl kinase inhibitor STI571 prevents motoneuron death
induced by ACM-SOD1G93A. (A) Flow diagram of experiment.
ACM-SOD1G93A was applied to 4 DIV spinal cord cultures acutely (for 90 min
when c-Abl-P peaks; see Figure 1) or chronically (3 days) either alone or in the
presence of c-Abl kinase inhibitor STI571 (1 μM). Phosphorylation of c-Abl was
measured at 4 and 7 DIV. Cell survival was measured at 7 DIV. (B) Graphs
showing fluorescence intensities (RIU) for c-Abl-P at 4 DIV when treated acutely
(90 min) with ACM-SOD1G93A alone or ACM-SOD1G93A plus STI571;
motoneurons (B1), interneurons (B2) and glial cells (B3) were identified by
immunostaining (as in Figure 1). (C1−3) Same as in (B), but c-Abl-P is
measured at 7 DIV when treated chronically (3 days) with ACM-SOD1G93A alone
or with STI571. (C4) c-Abl-P is measured at 7 DIV when treated chronically
(3 days) with ACM-SOD1WT alone or with STI571. (D,E) Graphs showing the
relative percentage of motoneurons that survived at 7 DIV, after being treated
with STI571 and ACM-SOD1G93A (D) or ACM-SOD1WT (E). Values represent
mean ± SEM from at least three independent experiments performed in
duplicate, analyzed by One-Way ANOVA followed by a Tukey post hoc test.
∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 relative to control conditions. #p < 0.05,
##p < 0.01 compared to survival with the ALS-causing ACM to at 7 DIV without
STI571.
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Nitroxidative Stress Induced by
ACM-hSOD1G93A Leads to Activation of c-Abl
Next we investigated possible mechanisms underlying the
induction of c-Abl activation by ACM-hSOD1G93A. Because
c-Abl is activated by oxidative stress and induces cell death (van
Etten, 1999; Klein et al., 2011; Schlatterer et al., 2011b), we
focused on the role of ROS/RNS. Indeed, we ﬁnd that H2O2–
induced oxidative stress caused a strong phosphorylation of c-Abl
in motoneurons, interneurons and astrocytes (see green squares
in Figure 1D1−3). Conversely, we wanted to determine whether
co-application of antioxidants with the toxic ACM-hSOD1G93A
can prevent c-Abl activation andmotoneuron cell death. Keeping
in mind that antioxidants can be used as a therapeutic strategy
for ALS, we tested several diﬀerent types of compounds with
antioxidant and/or free scavenger capacities, that also have
the biochemical properties to eﬀectively penetrate the blood–
brain-barrier: these include Trolox (a H2O soluble vitamin
E analog), esculetin, and 4,5-dihydroxy-1,3-benzenedisulfonic
(tiron). Trolox and esculetin were selected because they were
identiﬁed in a large screening assay as having strong antioxidant
activity, and as protecting the viability of mutant SOD1G93A-
expressing cell lines under stress conditions (Barber and Shaw,
2010). In a previous study, we tested multiple doses (ranging
from 100 to 100 μM), and found that 1 μM Trolox and 25 μM
esculetin reduced intracellular levels of ROS/RNS, and largely
prevented primary motoneuron cell death induced by ACM-
hSOD1G93A (Figure 3D), without aﬀecting the survival of control
motoneurons (Rojas et al., 2014; and shown in Figure 3E). We
also tested tiron, because it permeabilizes the mitochondrial
membrane and is more eﬀective in reducing oxidative stress
compared to the mitochondria-targeted antioxidant MitoQ
(Oyewole et al., 2014). We assessed the antioxidant capacity
and toxicity of multiple doses (ranging from 1 μM to 1 mM)
of this antioxidant (not shown), and found that 25 μM tiron
strongly reduces H2O2–induced oxidative stress (Supplementary
Figure S5) in the absence of cell death of control motoneurons
(Figure 3E).
Notably, all three antioxidants eﬀectively abrogated the
phosphorylation of c-Abl in motoneurons, interneurons and
astrocytes that is induced by acute (90 min exposure and tested
at 4 DIV; Figures 3B1−3) or chronic (3 days exposure and tested
at 7 DIV; Figures 3C1−3) treatment with ACM-hSOD1G93A
(Figures 3B,C show c-Abl-P intensities, while the percentage
of cells positive for c-Abl-P is shown in Supplementary Figure
S6). Importantly, motoneuron death was also largely prevented
following chronic co-application of ACM-hSOD1G93A and
Trolox, esculetin, or tiron (Figure 3D), whereas no increase
in the number of motoneurons was observed under control
conditions with use of any of these antioxidants (Figure 3E).
Together, our data indicate that counterbalancing the production
of ACM-hSOD1G93A-induced ROS/RNS protects motoneurons
from death by diminishing, at least in part, c-Abl activation.
ACM-hSOD1G93A Leads to Mitochondrial
Swelling and Membrane Depolarization
Because dysfunctional mitochondria constitute a major source
for elevating ROS production, and because mitochondrial
damage is a common feature in ALS patients and in mouse
models of ALS (Manfredi and Xu, 2005; Jaiswal et al., 2009;
Grosskreutz et al., 2010; Tan et al., 2014), we wanted to know
whether toxic factors released by hSOD1G93A-expressing
astrocytes induce mitochondrial defects in the neurons of
our culture system. We ﬁrst analyzed the morphology and
membrane potential of mitochondria in 4–5 DIV spinal cord
neurons under control conditions. To ﬂuorescently label
mitochondria, we used Tetramethylrhodamine Methyl Ester,
Perchlorate (TMRM; Figure 4); live time-lapse ﬂuorescence
microcopy imaging was accompanied by phase-contrast
images to select motoneurons on the basis of their large soma
(>20 μm) and extent at least ﬁve primary dendrites. The
TMRM ﬂuorescent labeling methods indicate that under basal
conditions, mitochondria in interneurons and motoneurons
of 4–5 DIV spinal cord cultures are mainly organized into
a tubular network (especially in the soma), with a few
isolated round mitochondria also visible (Figure 4B). To
get direct evidence for this, we visualized the ultra-structure
of mitochondria using transmission electron microscopy
(Figure 5); it was revealed that neurons in control 4–5 DIV
spinal cord cultures display prominent mitochondria, most
with an elongated shape and fewer with a globular morphology
(see Materials and Methods for identifying neuronal vs. glial
mitochondria).
We also studied the membrane potential and morphology
of mitochondria of 4–5 DIV spinal cord neurons that were
exposed to ACM-hSOD1G93A for diﬀerent times (minutes
to hours). TMRM staining showed that already short-term
exposure (30 min) of spinal cord neurons to ACM-hSOD1G93A
induces a decrease in the ﬂuorescent labeling in the majority
(but not all) of the neurons (Figure 4B). Quantiﬁcation
reveals that ∼60% of the neurons displayed a robust reduction
in the levels of TMRM ﬂuorescence (see Figures 4C,D for
scatter plots and graph with average data, respectively); it is
not clear why the TMRM signal in another population of
neurons (∼40%) remained unchanged. Because the trapping
of the TMRM dye inside the mitochondria matrix depends
on the mitochondrial membrane potential (m), the loss of
staining could be a consequence of mitochondrial membrane
depolarization, which can be induced by activation of uncoupling
proteins, or by the opening of the mitochondrial permeability
transition pore (mPTP); alternatively, it could be the result of
mitochondria degeneration. The results of two independent
sets of experiments support a depolarization event: (i) use of
mitoDsRed2 (a marker of the mitochondrial matrix used to assess
mitochondrial morphology and that is insensitive to m)
resulted in no obvious reduction in the number or intensity of
labeled mitochondria in cells treated with ACM-hSOD1G93A
for 0–90 min (not shown), indicating that mitochondria were
not lost; and (ii) ultra-structural analysis did not reveal any
reduction in the number of mitochondria in neurons that
had been exposed to ACM-hSOD1G93A for 4 h (Figure 5).
Electron microscopy images, however, did show that exposure
to ACM-hSOD1G93A induces mitochondrial alterations within
neurons with many mitochondria displaying a subtle, but
signiﬁcant, more swollen morphology (Figures 5A,B); this
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FIGURE 3 | Antioxidants reduce phosphorylation of c-Abl and prevent
motoneuron death induced by ACM-SOD1G93A. (A) Flow diagram of
experiment. ACM-SOD1G93A was applied to 4 DIV spinal cord cultures acutely
(for 90 min when c-Abl-P peaks; see Figure 1) or chronically (3 days), either
alone or in the presence of antioxidants Trolox (1 μM), esculetin. (25 μM),
(Continued)
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FIGURE 3 | Continued
or tiron (25 μM) Phosphorylation of c-Abl was measured at 4 and 7 DIV. Cell survival was measured at 7 DIV. (B) Graphs showing fluorescence intensities (RIU) for
c-Abl-P at 4 DIV when treated acutely (90 min) with ACM-SOD1G93A alone or ACM-SOD1G93A plus the antioxidants; motoneurons (B1), interneurons (B2) and glial
cells (B3) were identified by immunostaining (as in Figure 1). (C) Same as in (B), but c-Abl-P is measured at 7 DIV when treated chronically (3 days) with ACM-
SOD1G93A alone or in the presence of the antioxidants. (D,E) Graphs showing the relative percentage of motoneurons that survived at 7 DIV, after being treated with
antioxidants and ACM-SOD1G93A (D) or ACM-SOD1WT (E). Values represent mean ± SEM from at least 3 independent experiments performed in duplicate, analyzed
by One-Way ANOVA followed by a Tukey post hoc test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 relative to control conditions. #p < 0.05, ##p < 0.01, ###p < 0.001
compared to survival with the ALS-causing ACM to at 7 DIV without antioxidants.
kind of morphology is usually associated with the opening of
the mPTP (Ruiz et al., 2014). These observations collectively
indicate that ACM-hSOD1G93A induces rapid morphological
and physiological alterations in mitochondria. Because increased
action potential ﬁring is one the ﬁrst pathological events
detected in our in vitro model system (Fritz et al., 2013; Rojas
et al., 2014), we tested whether reducing hyper-excitability
with the Nav channel blocker spermidine (10 μM) is capable
of preventing the morphological alterations of neuronal
mitochondria induced by ACM-hSOD1G93A. Interestingly,
electron microscopy showed that co-application of ACM-
hSOD1G93A and spermidine for 4 h abrogates alterations in
the morphology of neuronal mitochondria (Figures 5A,B),
without changing the number of mitochondria (Figure 5C).
We also found that chronic exposure of ACM-hSOD1G93A plus
spermidine also prevents mitochondrial swelling (Supplementary
Figure S7).
Order of Pathological Events, and Interplay
between ROS and Mitochondria
Our data strongly indicate that upon ACM-hSOD1G93A exposure
the neuron’s hyper-excitability is the ﬁrst alteration to occur
(at 15–30 min), whereas activation of c-Abl is the last event
(at 60–90 min); by contrast, calcium inﬂux, ROS generation
and mitochondrial swelling and membrane depolarization are
all intermediate events, detectable starting at 30 min after
ACM-hSOD1G93A exposure. To determine the exact order
of these pathological events and mechanisms whereby c-Abl
activation mediates pathogenesis and death of motoneurons,
we studied the interplay between mitochondrial structure and
membrane physiology, oxidative stress, and c-Abl activation.
For this, ROS/RNS production (Figure 6) and c-Abl activation
(Figure 7) were measured in cultures that were exposed
to ACM-hSOD1G93A alone or in the presence of multiple
pharmacological compounds. We used blockers of Nav channels
(25 nM mexiletine, 100 nM riluzole and 10 μM spermidine; as
in Fritz et al., 2013; Rojas et al., 2014); chelation of extracellular
calcium (200 μM EGTA) to prevent calcium inﬂux; and
antioxidants (1 μM Trolox; as in Figure 3). To intent to prevent
mitochondrial alterations, we used Ru360, a selective inhibitor of
calcium uptake in mitochondria (Matlib et al., 1998), as well as
cyclosporin A (CsA) to inhibit the mPTP (Crompton et al., 1988,
1998; Broekemeier et al., 1989). For ROS/RNS production, we
measured intracellular DCF ﬂuorescence in spinal cord cultures
at 60 min of exposure to ACM-hSOD1G93A (Figure 6A), at the
peak of DCF ﬂuorescence levels as we have shown previously
(Rojas et al., 2014). In agreement with our previous work (and
repeated here for clarity), we found that co-incubation of ACM-
hSOD1G93A with diverse the Nav channel blockers mexiletine,
riluzole or spermidine eﬀectively inhibits the increase in DCF
ﬂuorescence levels induced by the toxic ACM (Figure 6B). In
addition, we found that the calcium chelator EGTA resulted in
lower intracellular DCF ﬂuorescence levels to degrees similar to
that observed in untreated cultures (Figure 6C). Co-application
of ACM-hSOD1G93A with mitochondrial protectors also strongly
reduced DCF ﬂuorescence; cyclosporin A being more eﬀective
than Ru360 (Figure 6D). These results indicate that ROS/RNS
is at least in part released by mitochondria when neurons are
exposed to ACM-hSOD1G93A.We used several control, including
ACM-hSOD1G93A plus Trolox which shows, as expected, that
ROS/RNS production was completely prevented (Figure 6E). We
also found that incubation of spinal cord cultures with ACM-
hSOD1WT alone or together with EGTA, cyclosporin A or Ru360
did not aﬀect DCF ﬂuorescence levels (Supplementary Figures
S8A–C); the ﬁnding that co-incubation of ACM-hSOD1WT with
the Nav channel blockers mexiletine, riluzole or spermidine also
does not alter DCF ﬂuorescence levels was shown previously
(Rojas et al., 2014).
To uncover the upstream events that contribute to c-Abl
activation in motoneurons and are mediated by ACM-
hSOD1G93A, we co-applied ACM from astrocytes expressing
hSOD1G93A plus the diﬀerent compounds (Figure 7A);
phosphorylation of c-Abl was measured at 90 min (i.e., at the
peak of c-Abl phosphorylation as shown in Figure 1D1). In
Figure 3 we already showed that application of the antioxidants
Trolox, esculetin or tiron prevent the increase in phosphorylation
of c-Abl. We also tested the eﬀects of Nav channel blockers on
ACM-induced c-Abl activation, and ﬁnd that co-application
of ACM-hSOD1G93A plus mexiletine, spermidine or riluzole
to spinal cord cultures partly prevents c-Abl phosphorylation
in motoneurons (Figure 7B). Finally, we ﬁnd that while the
calcium chelator EGTA slightly reduced ROS/RNS production
(Figure 7C), the mitochondrial protectors Ru360 or cyclosporin
A (Figure 7D) strongly prevent the c-Abl phosphorylation
induced by ACM-hSOD1G93A. Incubation of spinal cord cultures
with ACM-hSOD1WT alone or together with any of the above
indicated compounds did not alter c-Abl phosphorylation levels
(Supplementary Figures S8D–H). Collectively, our data indicate
that application of ACM-hSOD1G93A leads to the Nav-channel-
mediated hyper-excitability and calcium inﬂux that trigger
mitochondrial swelling and membrane depolarization; the
impaired mitochondria contribute, at least in part, to ROS/RNS
production that leads to activation of a lethal c-Abl signaling
cascade.
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FIGURE 4 | Mitochondrial potential membrane change after
ACM-hSOD1G93A. (A) Flow diagram of experiment. Four DIV spinal cord
cultures were incubated with TMRM (50 nM) during 30 min and then
exposed to ACM-hSOD1G93A for 30 min. Pictures were acquired using a
combination of real-time fluorescence and phase-contrast imaging.
(B) Representative pictures of an untreated neuron (0 min; upper images) or
treated for 30 min with ACM-SOD1G93A (lower images). Fluorescence
images, brightfield images and their merges are also shown. Scale bar in
main pictures 10 and 2 μm in insets. (C) Scatter plot showing the
percentage of TMRM fluorescence (arbitrary units) in every individual neuron
measured under the conditions indicated. Note that the majority (63%) of the
ACM-hSOD1G93A-treated neurons show a decrease in TMRM fluorescence
relative to the control condition, but that another neuronal population (37%)
does not. For clarity, we show all neurons (response + no response), those
that show reduced TMRM fluorescence after ACM-hSOD1G93A exposure
(response) and those that did not displayed TMRM alterations (no response).
(D) Graph showing the same data as in C. Values represent mean ± SEM
from at least three independent experiments performed in duplicate, analyzed
by One-Way ANOVA followed by a Tukey post hoc test. ∗∗∗p < 0.001
relative to control conditions.
Discussion
Deciphering the Sequence of Pathological
Events in Motoneurons with Use of the
ACM-hSOD1G93A Model System
Amyotrophic lateral sclerosis is, at least in part, a non-cell-
autonomous disease in which astrocytes that express ALS-
causing genes contribute to disease pathogenesis (Clement et al.,
2003; Ilieva et al., 2009). Compelling evidence documents that
primary astrocytes that express mutant SOD1-expressing and
are derived from mice (Nagai et al., 2007; Di Giorgio et al.,
2007; Castillo et al., 2013; Fritz et al., 2013; Rojas et al., 2014), rats
(Vargas et al., 2006; Cassina et al., 2008), and humans (Marchetto
et al., 2008) selectively kill motoneurons, but spare interneurons.
Remarkably, astrocytes that are diﬀerentiated from neuronal
progenitor cells (NPCs) derived either from post-mortem spinal
Frontiers in Cellular Neuroscience | www.frontiersin.org 12 June 2015 | Volume 9 | Article 203
Rojas et al. Role for c-Abl in ALS
FIGURE 5 | Exposure of primary spinal cord cultures to
ACM-hSODG93A induces mitochondria morphological alterations.
(A) Representative electron microscopy images of spinal cord cultures
treated for 4 h with ACM-hSOD1WT, ACM-hSOD1G93A alone or
ACM-hSOD1G93A plus spermidine (1 μM). Scale bar, 0.1 μm. (B) Graph
showing mitochondrial circularity of cells after treatment with the different
ACMs with or without spermidine. (C) Graph showing percentage of total
mitochondria size area of cultures under the same treatment shown in B,
classified in four groups: “small” (S; < 0.2 μm2), “medium” (M;
0.21–0.4 μm2), “large” (L; 0.41–0.6 μm2) and “extra large” (XL;
>0.6 μm2). Values represent mean ± S.E.M. from over 100 mitochondria
per condition, analyzed by one-way ANOVA followed by a Tukey post hoc
test. ∗p < 0.05 relative to ACM-hSOD1WT. ###p < 0.01 relative to
ACM-hSODG93A without spermidine.
cord tissue or skin biopsies from FALS (SOD1 and C9orf72)
and sALS patients, also display non-cell-autonomous toxicity,
and selectively kill motoneurons in a co-culture model system
(Haidet-Phillips et al., 2011; Meyer et al., 2014; Re et al.,
2014). Several pathological phenotypes observed in ALS patients
and animal models are recapitulated in these in vitro neuron-
astrocyte co-cultures, including those that are based on hyper-
excitability (Fritz et al., 2013; Rojas et al., 2014), mitochondrial
dysfunction (Cassina et al., 2008), and nitroxidative stress
(Cassina et al., 2008; Marchetto et al., 2008; Rojas et al., 2014).
However, the sequence of pathological events involved in these
changes has not been systemically studied. We believe that
unraveling the sequence has been diﬃcult because the co-cultures
used to study neuron-astrocyte interactions employ neurons
that grow on a feeder layer of astrocytes, hereby precluding
assessment of the temporal interplay between pathogenic events
(Vargas et al., 2006; Di Giorgio et al., 2007; Nagai et al., 2007;
Cassina et al., 2008; Marchetto et al., 2008; Haidet-Phillips et al.,
2011; Meyer et al., 2014; Re et al., 2014). Nagai et al. (2007)
establishes a unique in vitro ALS model system, and show
that exposure of spinal cultures to conditioned media obtained
from astrocytes that express mutated human SOD1 kills primary
motoneurons, as well as motoneurons derived from embryonic
mouse stem cells. We used (with some adaptions; see Materials
and Methods) this in vitro model system (Nagai et al., 2007),
along with pharmacological interventions and time-dependent
measurements at the single-cell level, to systematically unravel
the types and temporal order of pathological events induced
in motoneurons by ALS-ACM. In addition, the highly diluted
ACM-SOD1G93A that we use (seeMaterials andMethods) enables
us to show that motoneuron death is triggered by speciﬁc
soluble toxic mediator(s), and not by the lack of survival factors.
Making use of electrophysiological recordings, calcium imaging
and ﬂuorescent probes to detect ROS/RNS, and immunostaining
to identify surviving interneurons and motoneurons, we had
previously documented that exposure of primary WT spinal cord
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FIGURE 6 | Nav channel blockers, calcium chelator, mitochondria
protectors, and antioxidants prevent DCF fluorescence induced by
ACM-hSOD1G93A. (A) Flow diagram of experiment. Spinal cultures (4 DIV) were
exposed for 30 min to ACM-hSOD1G93A alone or together with Nav channel
blockers: mexiletine (25 nM), spermidine (10 μM), or riluzole (100 nM); calcium
extracellular chelator EGTA (200 μM); mitochondria protectors: CsA (10 μM) or
Ru360 (5 μM); or the antioxidant Trolox (1 μM). Next, cultures were incubated
with the membrane permeable ROS/RNS probe CM-H2DCF-DA and DCF
fluorescence was measured 30 min later in neurons using a combination of
real-time fluorescence and phase-contrast imaging. (B–E) Graphs showing the
intensity (arbitrary unit fluorescence; AUF) of DCF fluorescent cells after being
treated with ACM-hSOD1G93A alone or with the diverse Nav channel blockers
(B), calcium chelator EGTA (C), mitochondria protectors (D), or antioxidant
Trolox (E). Values represent mean ± SEM from at least three independent
experiments performed in duplicate, analyzed by One-Way ANOVA followed by
a Tukey post hoc test. ∗∗p < 0.01, ∗∗∗p < 0.001 relative to control conditions,
and ##p < 0.01, ###p < 0.001 compared to DCF fluorescence with
ALS-causing ACM to at 4 DIV without blockers.
cultures to ACM-hSOD1G93A leads to a rapid increase in the
excitability of neurons (detected already at 15–20 min) and to
inﬂux of calcium, which in turn generates intracellular ROS/RNS
followed by speciﬁc and robust motoneuron death (∼50%)
within a matter of days (Fritz et al., 2013; Rojas et al., 2014). In
the current study, we have studied the mechanisms that underlie
astrocyte-mediated toxicity of motoneurons in more detail, with
use of a variety of methods, including ROS/RNS detection with
the DCF ﬂuorescent probe; immunostaining to detect c-Abl
phosphorylation and the ratio of interneurons:motoneurons;
and two diﬀerent ﬂuorescent probes (TMRM and mitoDsRed2)
plus electron microscopy to determine mitochondrial function
and structure, respectively. We provide evidence here that
toxic factors released by hSOD1G93A–expressing astrocytes ﬁrst
increase Nav-channel-mediated excitability in neurons, which
in turn increases calcium inﬂux, and triggers functional and
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FIGURE 7 | Nav channel blockers, calcium chelator, mitochondria
protectors, and antioxidants reduce c-Abl activation induced by
ACM-hSOD1G93A. (A) Flow diagram of experiment. Spinal cultures (4 DIV)
were exposed for 90 min to ACM-hSOD1G93A alone or together with Nav
channel blockers: mexiletine (25 nM), spermidine (10 μM), or riluzole
(100 nM); calcium extracellular chelator EGTA (200 μM); mitochondria
protectors: CsA (10 μM) or Ru360 (5 μM). Next, immunostaining was
performed to detect phosphorylated c-Abl in motoneurons (MAP2+/SMI32+
cells). (B–D) Graphs showing the c-Abl-P intensity after being treated with
ACM-hSOD1G93A alone or with the diverse Nav channel blockers (B),
calcium chelator EGTA (C), or mitochondria protectors (D). Values represent
mean ± SEM from at least three independent experiments performed in
duplicate, analyzed by One-Way ANOVA followed by a Tukey post hoc
test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 relative to control conditions,
and #p < 0.05, ##p < 0.01 compared to DCF fluorescence with
ALS-causing ACM at 4 DIV without blockers or antioxidants.
structural changes in mitochondria. Our data indicate that
ROS/RNS, generated at least in part through mitochondrial
alterations, activate c-Abl signaling. Although mitochondria
are a main source of ROS production for most cells, it has
been well established that ROS can be produced at multiple
sites in mammalian cells, including by NADPH oxidase (Nox),
amino acid oxidases, cytochrome P450 enzymes, cycloxygenases,
lipoxygenases and xanthine oxidase (Turrens, 2003). Of interest
is also that ROS produced by these diﬀerent sources does not
always activate pathophysiological cellular processes, but can
also function as a beneﬁcial signaling messenger (Massaad and
Klann, 2011). In ALS pathology, toxic ROS can be produced by
dysfunctional mitochondria (Tan et al., 2014; and see below), as
well as through Nox enzymes (Wu et al., 2006; Marden et al.,
2007; Harraz et al., 2008). Additional studies, which are out of
the scope of this present study, should be performed to identify
which other source(s), in addition to mitochondria, could be
involved in the production of ROS in the ACM-hSOD1G93A
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model system. Our ﬁndings collectively lead us to conclude
that the key hallmarks of ALS, including ROS/RNS production
and mitochondrial swelling and membrane depolarization, are
recapitulated in our in vitro neuron-astrocyte model. We predict
that our focus on elucidating the mechanisms of non-cell-
autonomous motoneuron pathology and death, and on the
contribution of Nav-channels, ROS/RNS, mitochondria and
the c-Abl pathway, will yield advances for the use and/or
development of therapeutic interventions for this devastating
disease.
Dysfuntional Mitochndria as a Source of
ROS/RNS
Mitochondria participate in energy metabolism, intracellular
calcium homeostasis, production of intracellular ROS, and
regulation of apoptosis (Nicholls, 2009; Rasola and Bernardi,
2011; Maryanovich and Gross, 2013). Morphological and
functional abnormalities in mitochondria are a common feature
of ALS, and are detected in biopsied and post-mortem tissue from
symptomatic sALS and fALS patients, as well as in mutant SOD1
mouse models and the cell cultures derived from these mice
(reviewed in Manfredi and Xu, 2005; Bento-Abreu et al., 2010;
Grosskreutz et al., 2010; Tan et al., 2014). Degenerated, vacuolized
and swollen mitochondria are detected in transgenic mice that
express mutations in SOD1, around the time when clinical
symptoms appear (Dal Canto and Gurney, 1995; Wong et al.,
1995; Kong and Xu, 1998). Moreover, ultra-structural analysis
reveals that mitochondrial swelling is detected in spinal cord
motoneurons of hSOD1G93A transgenic mice at P14, 2–3 months
prior to the time that motoneurons degeneration is visible, and
before clinical symptoms are manifest (Bendotti et al., 2001);
these ﬁndings underscore early mitochondrial abnormalities in
this mouse model and suggest that mitochondrial dysfunction
might contribute to motoneuron pathology. Electron microscopy
also shows that in our in vitro ALS model system mitochondrial
swelling is an early event in motoneuron pathogenesis, and
is induced by soluble mediator(s) secreted by hSOD1G93A-
expressing astrocytes. Swelling of mitochondria may be caused
by activation of mPTP, a voltage-dependent, high conductance
mega channel whose opening is critically regulated and triggered
by various processes, including matrix calcium accumulation,
ROS, and adenine nucleotide depletion (Miller, 1998; Kroemer
and Reed, 2000; Rasola and Bernardi, 2011; Bernardi and Di Lisa,
2015).
Our ﬁndings with cyclosporine A and Ru360, along with
results from use of mitochondrial ﬂuorescent probes, suggest
that hSOD1G93A astrocyte-triggered abnormalities are caused, at
least in part, by the accumulation of calcium in mitochondria;
the calcium uptake could induce the opening of mPTP in
motoneurons which is followed by a rapid loss of m,
uncontrolled matrix calcium and oxidative species release, matrix
swelling and eventually rupture of the outer membrane, and
release of apoptogenic factors (Rasola and Bernardi, 2011). Thus
the opening of mPTP may induce both apoptotic and necrotic
death signal
Because mitochondria predominantly generate superoxide
anion (O2•−) as a by-product of the respiratory chain functioning
(Murphy, 2009), which is not detectable by the DCF probe
used in this study (Myhre et al., 2003), our ﬁndings indicate
that other reactive oxygen and nitrogen species contribute to
the motoneuron pathology observed in our model system. On
the other hand, DCF does detect hydrogen peroxide (H2O2; in
combination with cellular peroxidases), hydroxyl radicals (•OH),
and peroxynitrite (ONOO−; Estévez et al., 1999; Myhre et al.,
2003; Gomes et al., 2005; Martin et al., 2007; Kalyanaraman
et al., 2012). Of particular interest is ONOO− which is formed
from •NO and O2•− and is strongly implicated in several
models of ALS, but is predominantly detected by the amounts
of 3-nitrotyrosine formation in proteins (Abe et al., 1997;
Bruijn et al., 1997; Beckman et al., 2001; Radi, 2004; Wu
et al., 2006). Reactive and SOD1G93A-expressing astrocytes are
a major source of •NO, which then can target neighboring
cells and aﬀects the survival of WT motoneurons (Vargas
et al., 2006; Cassina et al., 2008). Based on these reports, we
hypothesize that conditioned media derived from hSOD1G93A-
expressing astrocytes includes •NO and/or leads to the generation
of •NO in the WT astrocytes that are present within spinal
cord cultures upon acute exposure of the toxic ACM; this
•NO in turn permeates into neurons, where it interacts with
the intracellular O2•− produced by mitochondria, and forms
ONOO−.
Activation of c-ABL in ALS
Active c-Abl is implicated in a variety of neurodegenerative
diseases, including Alzheimer’s (Alvarez et al., 2004; Cancino
et al., 2008; Estrada et al., 2011; Gonzalez-Zuñiga et al., 2014)
and Parkinson’s diseases (Imam et al., 2011). Recently, Katsumata
et al. (2012) reported a signiﬁcant increase in c-Abl expression
in post-mortem spinal cord tissues from sALS patients, and
in the spinal cord of symptomatic hSOD1G93A mice; they also
demonstrated that oral administration of the c-Abl inhibitor
dasatinib to animals aged P56–P120 attenuates motoneuron
loss, alleviates motor dysfunction, and signiﬁcantly increases
lifespan (Katsumata et al., 2012). In the current study, we also
document that phosphorylation of c-Abl is signiﬁcantly increased
in the brain and spinal cord of symptomatic hSOD1G93A
mice; furthermore, we show that activated c-Abl is detectable
in symptomatic hSOD1G86R mice. Importantly, exposure of
WT spinal cord cultures to conditioned media derived from
astrocytes expressing SOD1 (SOD1G93A or SOD1G86R) TDP43
(TDP43A315T) mutants, activates the c-Abl tyrosine kinase in
WT motoneurons. Our results show that activation of c-Abl
in two completely unrelated ALS models leads to the death
of motoneurons via non-cell autonomous processes. We used
our in vitro ACM-hSOD1G93A model system to investigate
the potential causes of c-Abl activation in ALS: in agreement
with earlier studies, which report that oxidative stress can
induce c-Abl activation (van Etten, 1999; Klein et al., 2011;
Schlatterer et al., 2011a), we found that ROS (H2O2) increases
c-Abl phosphorylation, and that co-application of antioxidants
plus ACM-hSOD1G93A strongly reduce activation of this kinase,
in a manner similar to that of the c-Abl inhibitor STI571.
Moreover, we also show that reducing c-Abl activation by
antioxidants as wells as by STI571 protects astrocyte-mediated
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toxicity in motoneurons. Experiments with use of mitochondrial
protectors (cyclosporine A and Ru360) point to a key role for
mitochondrial-produced ROS in the activation of c-Abl. Based on
these ﬁndings, we hypothesize that inhibition of ROS production
(by protecting mitochondrial dysfunction or by application of
antioxidants) in ALS animals might largely prevents motoneuron
pathology and signiﬁcantly extends the lifespan of these mice.
Hyper-Excitability is a Primary Pathological
Event in Astrocyte-Triggered Motoneuron
Degeneration
Our current and earlier ﬁndings with use of the ACM in vitro
model (Fritz et al., 2013; Rojas et al., 2014) strongly implicate
hyper-excitability as a critical pathological event in astrocyte-
triggered motoneuron degeneration, and show that it occurs
upstream of mitochondrial impairment, ROS production, and
c-Abl activation. The use of electrophysiological recordings in
motoneurons in acute slice preparations of neonatal SOD1G93A
mice (P4–P10), reveals that increased excitability (van Zundert
et al., 2008) precedes the mitochondrial damage that is detected
at 2 weeks of postnatal life (Bendotti et al., 2001). Additional
studies also show that electrophysiological abnormalities in
motoneurons are the earliest physiological alterations detected
in diverse ALS rodent models (Kuo et al., 2005; Bories et al.,
2007; Pambo-Pambo et al., 2009; Quinlan et al., 2011; van
Zundert et al., 2012). Hyper-excitability has been reported
in fALS and sALS patients (van Zundert et al., 2012), and
also in induced pluripotent stem cell-derived motoneurons
(i-motoneurons) generated from ALS patients that harbor
mutations in SOD1, C9orf72, and FUS/TLS (Wainger et al.,
2014). Generation of action potentials, and hence of membrane
excitability, is regulated by the number and functioning of Nav
and Kv channels on neuronal cells. Currently, we have little
insight into the mechanism responsible for hyper-excitability,
but we do know that it is related to an increase in persistent
Nav channel currents (van Zundert et al., 2008, 2012; Fritz
et al., 2013; Pieri et al., 2013), and to a reduction in the
amplitude of the delayed-rectiﬁer K channel current (Wainger
et al., 2014). The possibility that a factor(s) released by ALS
astrocytes regulates the function and/or expression of these
ion channels is intriguing, and its identiﬁcation is of great
importance. Independent of the mechanisms, pharmacological
assays in vitro show that decreasing the activity of Nav channels
of motoneurons by co-application of ACM-hSOD1G93A plus the
Nav channel blockers mexiletine, riluzole or spermidine (Fritz
et al., 2013; Rojas et al., 2014; current study), or by increasing
Kv channel activity via treatment of ALS i-motoneurons with
retigabine (Wainger et al., 2014), inhibits hyper-excitability and
improves motoneuron survival. These compounds may also be
promising candidate drugs for attenuating pathogenesis and
delaying the onset of disease-speciﬁc symptoms of fALS and sALS
patients; neurophysiological studies in both types of patients
have uncovered neuronal hyper-excitability (van Zundert et al.,
2012). In addition, because these patients are similar to each
other in terms of other pathological events (e.g., mitochondrial
impairment and production of ROS), clinical symptoms, and
the beneﬁts gained from treatment with riluzole (a non-speciﬁc
Nav channel blocker; Bellingham, 2011), we hypothesize that
motoneuron hyper-excitability represents a general feature of
sALS and fALS patients, and that motoneuron death is triggered
by activation of a common fatal pathogenic signaling pathway
(van Zundert et al., 2012). Further support for this hypothesis will
come from results of phase II trial that have been initiated by the
ALS Therapy Alliance (ATA) and the Northeast ALS (NEALS)
Consortium with use of mexiletine to treat sALS patients. Our
ﬁndings also underscore the need for further tests in diverse
ALS animal models and in ALS patients with the compounds
that successfully prevent motoneuron damage in ALS neuron-
astrocyte in vitro systems: within this context, the anti-oxidants
Trolox and esculetin are especially promising because of their
strong antioxidant activity and their ability to cross the blood-
brain-barrier (Barber and Shaw, 2010).
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